$55.75
+5.2%GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
WGS • NASDAQ
| GeneDx Holdings Corp. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
427.5M | 305.5M | 202.6M | 234.7M | 212.2M | 179.3M | 196.2M | |
GROSS PROFIT | |||||||
(129.4M) | (111.1M) | (112.6M) | (261.4M) | (228.8M) | (175.3M) | (113.4M) | |
298.2M | 194.4M | 90M | -26.8M | -16.6M | 4M | 82.8M | |
OPERATING INCOME | |||||||
(311.3M) | (217.6M) | (270.6M) | (640.9M) | (429.5M) | (246M) | (113.2M) | |
(239.2M) | (168.5M) | (194.7M) | (338.2M) | (318.7M) | (163.9M) | (68.8M) | |
(72M) | (45.7M) | (58.3M) | (86.2M) | (105.2M) | (72.7M) | (34.9M) | |
-11.8M | -23.2M | -180.6M | -667.7M | -446.1M | -242M | -30.4M | |
PRE-TAX INCOME | |||||||
(2.5M) | (3M) | (0.0) | (3.2M) | (2.8M) | (2.5M) | (783K) | |
-2.5M | -3M | 1.1M | -666K | -2.8M | -2M | 205K | |
(0.0) | (3.4M) | (17.6M) | (216.5M) | (5.7M) | (9.4M) | (9.5M) | |
-9.3M | -29.4M | 3.9M | 69.6M | 200.8M | 654K | 709K | |
-21.1M | -52.6M | -176.7M | -598M | -245.4M | -241.3M | -29.7M | |
NET INCOME | |||||||
-116K | -343K | -926K | -49.1M | (0.0) | (0.0) | (0.0) | |
-21M | -52.3M | -175.8M | -549M | -245.4M | -241.3M | -29.7M |
WGS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | October 28, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 18, 2025 | September 17, 2025 | 2025 |
Continue your WGS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.